^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCND1 (Cyclin D1)

    i
    Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
    1d
    Hyperplasia suppressor gene inhibits the progression of malignant meningioma via the Wnt/β-catenin signaling pathway. (PubMed, Transl Cancer Res)
    This study identifies HSG as a critical tumor suppressor in malignant meningioma that restrains tumor aggressiveness by dampening the Wnt/β-catenin cascade. These novel findings highlight the HSG-Wnt/β-catenin axis as a promising therapeutic target, offering new translational strategies for the management of this highly aggressive intracranial tumor.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9)
    1d
    Effects of pomegranate seed extract and ellagic acid on miR-16-5p and miR-34a-5p expression, cell cycle, and apoptosis in MCF-7 cells. (PubMed, Res Pharm Sci)
    EA and PSE antioxidants increased hsa-miR-16-5p and hsa-miR-34a-5p expression, induced apoptosis, decreased cell proliferation, and stopped cancer cells in the G1 phase. Therefore, they can be considered promising compounds for helping the treatment of breast cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • MIR34A (MicroRNA 34a-5p) • MIR16 (MicroRNA 16) • SIRT1 (Sirtuin 1)
    1d
    Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. (PubMed, Blood Adv)
    In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • FANCE (FA Complementation Group E)
    2d
    Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=106, Completed, Alliance for Clinical Trials in Oncology | Phase classification: P2 --> P1
    Phase classification
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    lenalidomide • Zydelig (idelalisib)
    2d
    Amplification and Overexpression of Cyclin D1 in Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Targeted Next-Generation Sequencing Study. (PubMed, Mod Pathol)
    In addition, tumor cells exhibited a type II EBV latency pattern (LMP1+/EBNA2-) in 84.6% of cases, and LMP1 expression correlated with larger tumor size (p=0.021). Taken together, these findings support a role for EBV-driven activation of the cyclin D1 pathway and suggest that EBV-LMP1-CCND1 signaling may contribute to the pathogenesis of IFDCS.
    Journal • Next-generation sequencing
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ATM (ATM serine/threonine kinase) • CCND1 (Cyclin D1)
    |
    ATM mutation • EZH2 mutation
    |
    TruSight Oncology 500 Assay
    3d
    Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms: When Morphologic Ambiguity is Deceptive. (PubMed, Am J Surg Pathol)
    Our study demonstrates a high sensitivity (100%) and specificity (93%) in utilizing cyclin D1 to distinguish MHNs (mature phenotype) from MS (immature phenotype) in diagnostic practice. It is particularly valuable in challenging scenarios of MS with the absence of immature/myeloid lineage-defining markers (MPO, CD34, or CD117) and provides a cost-effective tool to resolve this diagnostic pitfall, ensuring an accurate subclassification.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CCND1 (Cyclin D1) • CD34 (CD34 molecule)
    3d
    High-grade Endometrial Stromal Sarcoma With a Novel ING3::BCOR Fusion. (PubMed, Int J Gynecol Pathol)
    HGESS with BCOR fusion should be considered in tumors with a combination of spindle cell growth, myxoid background, foci of coagulative necrosis, diffuse cyclin D1 positivity, and a negative hormone receptor status. Accurate diagnosis requires an integrated approach that combines histopathologic evaluation, IHC, and molecular testing.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • CCND1 (Cyclin D1) • BCOR (BCL6 Corepressor) • CD34 (CD34 molecule) • ALK1 (Activin A Receptor Like Type 1) • MME (Membrane Metalloendopeptidase)
    6d
    Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions. (PubMed, Res Sq)
    In the absence of BAMPs, cells carrying oncogenic KRAS mutations are unable to attain their full penetrance in proliferation. Overall, this work unveils the long-overlooked role of branched actin-driven cell morphology in the functionalization of KRAS mutants as potent oncogenes.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CCND1 (Cyclin D1) • RAC1 (Rac Family Small GTPase 1) • TIAM1 (TIAM Rac1 Associated GEF 1)
    |
    RAS mutation
    6d
    Clinicopathological features of pancreatic solid pseudopapillary neoplasm: A retrospective single-center study of 32 cases in Guangzhou, China. (PubMed, Pathol Res Pract)
    Pancreatic SPN is a low-grade malignant neoplasm increasingly identified incidentally in young women. While preoperative suspicion relies on characteristic imaging, definitive diagnosis requires histopathological evaluation and demonstration of hallmark nuclear β-catenin expression. Surgical resection remains the mainstay of treatment with favorable outcomes in most cases. However, significant biological heterogeneity exists; patients with high-risk features-such as high-grade transformation or extreme Ki-67 elevation-warrant closer individualized long-term surveillance.
    Retrospective data • Journal
    |
    CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MME (Membrane Metalloendopeptidase)
    7d
    NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ABL1 (ABL proto-oncogene 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • POLE (DNA Polymerase Epsilon) • CCND1 (Cyclin D1) • BAP1 (BRCA1 Associated Protein 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • POLD1 (DNA Polymerase Delta 1) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • BRD4 (Bromodomain Containing 4) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • FANCC (FA Complementation Group C)
    |
    PALB2 mutation • BRIP1 mutation
    |
    FoundationOne® CDx
    |
    Lynparza (olaparib)
    7d
    Regulation of the KEAP1/NRF2 pathway by claudin-2-targeted lymphoid enhancer-binding factor 1 binding in gastric cancer progression. (PubMed, J Physiol Pharmacol)
    Reducing LEF1 levels counteracted the effects of CLDN2 on GC cell growth and KEAP1/NRF2 pathway. Increased levels of CLDN2, which modulate the LEF1 and KEAP1/NRF2 pathways, are correlated with GC progression and may be used as a marker for poor prognosis.
    Journal
    |
    CCND1 (Cyclin D1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • CLDN2 (Claudin 2)
    7d
    Novel peptide Aurein1.2 derivative induces cytotoxicity in cervical cancer SiHa and HeLa cells by apoptosis and cell cycle arrest. (PubMed, Toxicol Appl Pharmacol)
    In vivo experiments showed that Aurein1.2 m effectively suppressed the growth of SiHa-derived tumors without inducing any adverse effects. In conclusion, Aurein1.2 m exerts cytotoxicity against cervical cancer cells by promoting mitochondria-dependent apoptosis and arresting the cell cycle via c-Myc inhibition, highlighting its potential for development as an anti-cervical cancer therapeutic agent.
    Journal • PARP Biomarker • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)